KTTA (44) HIND (35) BOLT (28) RKTO (44) ⌘ Pro Terminal →

Lipocine Inc. (LPCN) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell LPCN stock right now?

Lipocine Inc. (LPCN) currently earns a Roarable Rating of D- (Sell — SELL) with 37/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is LPCN's 12-month price target and RQD AI Jury consensus?

LPCN's 12-month base price target is $1.38 (range $1.08 to $12.99), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$1.52 +0.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.52

Lipocine Inc. (LPCN) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $12.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.52 (-0.07%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LPCN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY LPCN SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (35% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 30.9 (OVERSOLD (<32))

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.72-9.3% Next Q

Q2 (-2Q)

Grade D$1.56-7.7% Next Q

Q3 (-1Q)

Grade D$1.44+5.6% Next Q

Current

Grade D-$1.52-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LPCN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LPCN currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.99) and Max Pain ($1.60) forces dealer call-delta covering toward $12.99.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LPCN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LPCN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

30.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$1.52H: $12

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on LPCN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (25)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (45)

14/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like LPCN

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LPCN)

✓Walkthrough of LPCN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LPCN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.76%📐 HORIZONTAL RANGE

2026-10-30O $1.50H $1.52L $1.42C $1.52VOL 112.0K

RES: $3.26SUP: $1.28SMA50: $1.99SMA200: $3.91

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LPCN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LPCN Butterfly Map → + Track LPCN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LPCN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LPCN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LPCN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LPCN)

Health Care Rank #764 of 1016 ⚔️ KTTA vs LPCN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LPCN vs. KTTA, HIND, BOLT, RKTO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lipocine Inc. (LPCN) ranks #764 by composite RQD confidence (37/100, grade D-) and #874 by equity capitalization ($12.5M). Within this direct 5-issuer industry benchmark cohort, LPCN leads on earnings valuation at N/A trailing P/E, while LPCN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KTTA currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with LPCN at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LPCN ACTIVE Lipocine Inc.	D-	37/100	—	—	-35.0%	+0.66%	$12.5M	Benchmark Subject
KTTA Pasithea Therapeutics Corp.	D	44/100	—	—	-35.0%	-5.95%	$12.3M	/ktta-vs-lpcn →
HIND Vyome Holdings Inc.	D-	35/100	—	68.4%	-35.0%	+1.74%	$12.3M	/hind-vs-lpcn →
BOLT Bolt Biotherapeutics Inc.	E	28/100	—	—	-35.0%	-3.34%	$12.3M	/bolt-vs-lpcn →
RKTO Rocket One Inc.	D	44/100	—	—	-35.0%	-4.96%	$12.8M	/rkto-vs-lpcn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001535955

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lipocine Inc. (LPCN) reported GAAP revenue of $2.0M (-82.3% vs. FY2024 revenue of $11.2M , and +169.3% cumulative change since FY2023) , GAAP net income of -$9.6M, operating cash flow of -$9.8M, and free cash flow of -$9.8M (-644.3% YoY). On the balance sheet, LPCN closed FY2025 with $17.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.0M	-$9.6M	-$9.8M	-$9.8M	$17.0M	—
FY2024 (FY)	2024-12-31	$11.2M	$10.0K	-$1.2M	-$1.3M	$22.5M	—
FY2023 (FY)	2023-12-31	-$2.9M	-$16.4M	-$11.9M	-$11.9M	—	—

3. LPCN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LPCN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lipocine Inc. (NASDAQ: LPCN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.52 (+0.66% 1D, market cap $12.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LPCN ranks #764 in composite RQD confidence.

How does LPCN compare to KTTA and HIND in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LPCN carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KTTA (Pasithea Therapeutics Corp.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M) and HIND (Vyome Holdings Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, LPCN leads on earnings multiple (N/A) while LPCN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LPCN?

Per LPCN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001535955), Lipocine Inc. generated $2.0M in revenue (-82.3% YoY), -$9.6M in net income, and -$9.8M in free cash flow against $17.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LPCN trading relative to its 50-day, 200-day, and 52-week technical levels?

LPCN last traded at $1.52 (+0.66% on volume of 139,129 shares), positioning the stock -23.62% below its 50-day simple moving average ($1.99) and -61.13% below its 200-day simple moving average ($3.91). Across its 52-week range of $1.40 to $12.37, LPCN sits at the 1.1% percentile with a 14-day RSI of 30.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.33 to $1.71).

LPCN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell LPCN stock right now?

Lipocine Inc. (LPCN) currently earns a Roarable Rating of D- (Sell — SELL) with 37/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is LPCN's 12-month price target and RQD AI Jury consensus?

LPCN's 12-month base price target is $1.38 (range $1.08 to $12.99), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: LPCN RQD Cockpit LPCN 12M Forecast LPCN Earnings & Move LPCN Dividends & DRIP LPCN Insiders & 13F LPCN Whale Options LPCN Profit Sankey LPCN News & Why